N 6 -methyladenosine (m6A) is the most abundant modified base in eukaryotic mrnA and has been linked to diverse effects on mrnA fate. current mapping approaches localize m6A residues to transcript regions 100-200 nt long but cannot identify precise m6A positions on a transcriptome-wide level. here we developed m6A individual-nucleotide-resolution cross-linking and immunoprecipitation (micliP) and used it to demonstrate that antibodies to m6A can induce specific mutational signatures at m6A residues after ultraviolet light-induced antibody-rnA cross-linking and reverse transcription. We found that these antibodies similarly induced mutational signatures at N 6 ,2′-O-dimethyladenosine (m6Am), a modification found at the first nucleotide of certain mrnAs. using these signatures, we mapped m6A and m6Am at single-nucleotide resolution in human and mouse mrnA and identified small nucleolar rnAs (snornAs) as a new class of m6A-containing non-coding rnAs (ncrnAs).
N 6 -methyladenosine (m6A) is the most abundant modified base in eukaryotic mrnA and has been linked to diverse effects on mrnA fate. current mapping approaches localize m6A residues to transcript regions 100-200 nt long but cannot identify precise m6A positions on a transcriptome-wide level. here we developed m6A individual-nucleotide-resolution cross-linking and immunoprecipitation (micliP) and used it to demonstrate that antibodies to m6A can induce specific mutational signatures at m6A residues after ultraviolet light-induced antibody-rnA cross-linking and reverse transcription. We found that these antibodies similarly induced mutational signatures at N 6 ,2′-O-dimethyladenosine (m6Am), a modification found at the first nucleotide of certain mrnAs. using these signatures, we mapped m6A and m6Am at single-nucleotide resolution in human and mouse mrnA and identified small nucleolar rnAs (snornAs) as a new class of m6A-containing non-coding rnAs (ncrnAs).
m6A is the most prevalent modified base in mRNA [1] [2] [3] [4] . Although m6A was detected in poly(A) + RNA in the 1970s 3, 4 , it was not widely accepted as a component of mRNA until recent transcriptome-wide mapping studies showed that m6A is found in several thousand transcripts, typically near the stop codon, but also in the coding sequence, 3′ UTR and 5′ UTR of mRNAs 1, 2 .
The current m6A mapping approach, methyl-RNA immunoprecipitation and sequencing (MeRIP-Seq, also called m6A-Seq) 1, 2 , involves the immunoprecipitation of ~100-nt-long RNA fragments with m6A-specific antibodies. The approach generates m6A peaks, but it does not identify specific m6A residues.
Identifying m6A residues is challenging. Adenosine methylation appears to be restricted to adenosines in an R-A*-C context (where R denotes G or A, and A* denotes methylatable A), and recent transcriptome-wide m6A maps 1, 2, 5 suggest the broader consensus motif DRACH (where D denotes A, G or U, and H denotes A, C or U). Although DRACH motifs are prevalent, only a fraction are methylated in vivo 1, 2 . One can predict exact m6A positions from MeRIP-Seq peaks by searching for DRACH motifs near the point of highest read coverage 5 . However, m6A often appears in clusters, which can result in large peaks spanning several m6A residues 1 . Additionally, multiple DRACH motifs can be present underneath a peak, making it difficult to predict the specific methylated adenosine(s).
Unlike other base modifications such as 5-methylcytosine, m6A and A have nearly identical chemical properties; this has prevented the development of a chemical method for the selective modification of m6A residues for detection at single-nucleotide resolution 6 . Moreover, m6A does not introduce errors during reverse transcription that would allow for direct mapping of its position 7 . Thus, a major goal is to develop a chemical signature that indicates the precise location of m6A residues in the transcriptome.
We reasoned that antibodies to m6A could be used to create such a highly selective mark: reverse transcription of RNA that was UV-cross-linked to the antibody would result in mutations or truncations in the cDNA, indicating the presence of the bound protein. This strategy resembles RNA cross-linking and immunoprecipitation (CLIP)-based techniques that cross-link proteins to RNA in living cells to enable mapping of RNA-binding sites throughout the transcriptome [8] [9] [10] [11] .
Here we show that reverse transcription of RNA cross-linked to certain m6A antibodies resulted in a highly specific pattern of mutations or truncations in the cDNA that enabled precise identification of m6A residues. These mutational signatures also enabled identification of the related modified nucleotide m6Am, which is the first nucleotide after the 7-methylguanosine cap of certain mRNAs 12 . Using these signatures, we mapped m6A and m6Am residues throughout the transcriptome at singlenucleotide resolution. results determining the mutational profile of antibodies to m6A Because UV-induced RNA-protein cross-links can be highly variable 13 , we first established the mutational signatures of different commercially available antibodies to m6A. To do this, we cross-linked an in vitro-transcribed RNA containing a single m6A to different m6A antibodies. The RNA was reverse transcribed, and the cDNA was sequenced to identify mutations introduced during reverse transcription 9, 14 . Some antibodies induced an unpredictable pattern of substitutions at different positions relative to the m6A residue, making it difficult to unambiguously determine the position of the m6A (Fig. 1a,b) . However, other antibodies resulted in more consistent substitution patterns. For example, the Abcam antibody (Online Methods) induced a nucleotide substitution at the invariant cytosine residue adjacent to the m6A as well as at the m6A itself (Fig. 1a) .
We also analyzed truncations and found that the Synaptic Systems (SySy) polyclonal antibody (Online Methods) efficiently induced truncations at the +1 position relative to the m6A (Fig. 1b) . Although other antibodies also induced specific mutation patterns, the Abcam and SySy polyclonal antibodies were chosen for further investigation because of their high immunoprecipitation efficiency and predictable patterns of cross-link-induced substitutions and truncations.
transcriptome-wide characterization of cross-linking sites
To exploit these mutational signatures for transcriptome-wide mapping of m6A, we developed m6A individual-nucleotide-resolution cross-linking and immunoprecipitation (miCLIP). In miCLIP, cellular RNA is sheared and cross-linked to anti-m6A using UV light (Fig. 1c) . RNA fragments cross-linked to antibody are then purified and converted into a cDNA library according to the iCLIP protocol 9 . Cross-link-induced mutations and truncations introduced during reverse transcription are then analyzed to determine the precise positions of m6A throughout the transcriptome.
We generated two miCLIP libraries from human embryonic kidney (HEK293) cells using total cellular RNA cross-linked to either Abcam or SySy antibodies. Comparison of the two libraries revealed strong enrichment of C→T, but not of any other transitions, in the Abcam library (Supplementary Fig. 1a,b) . Thus, C→T transitions may serve as a signature mutation for mapping m6A with miCLIP using the Abcam antibody.
To determine whether C→T transitions are markers of m6A in cellular RNA, we examined these mutations at known m6A residues in human 18S and 28S rRNA 15 . Mapped reads exhibited a high frequency of C→T transitions at +1 positions relative to these m6A residues, whereas reads covering a non-methylated site did not show such enrichment (Fig. 1d) . Strikingly, quantitative analysis across the length of the 18S and 28S transcripts showed that C→T transitions were enriched by ~500-fold and ~1,000-fold at m6A positions, respectively (Fig. 1e) . To test whether the Abcam antibody induced other mutations near m6A residues, we analyzed single-nucleotide substitutions around RAC tripletsthe core m6A motif-throughout the transcriptome. The only mutation seen with high frequency at these triplets was the C→T transition at position +1 relative to the A ( Supplementary  Fig. 1c) . Thus, the Abcam antibody induced C→T transitions at m6A in a highly position-specific manner.
Notably, the SySy antibody, which primarily induced truncations, also induced C→T transitions at the +1 position. Thus, C→T transitions may be a common feature with antibodies to m6A. However, in the SySy library, other substitutions were present, and the mutations occurred with lower positional accuracy (Supplementary Fig. 1d ). Because in vitro analysis indicated that the SySy antibody efficiently induced cDNA truncations at the +1 position of m6A (Fig. 1b) , truncations were used as this antibody's mutational signature.
identification of m6A using antibody-induced mutations To identify m6A residues throughout the transcriptome, we generated independent maps of human m6A residues in HEK293 mRNA using the Abcam and SySy antibodies. npg
For the Abcam library, we prepared short antibody-bound RNA fragments (~35 nt) and used paired-end sequencing to reduce mutation noise (Online Methods). Mapping these reads to the reference genome resulted in ~40-nt-wide peaks, unlike the ~200-nt-wide peaks seen in MeRIP-Seq (Supplementary Fig. 2 ). Combining reads from four replicates resulted in the identification of 80,774 peaks on mRNA and 92,068 C→T transitions at 48,694 different genomic positions.
In the SySy library, peaks were similar in width and overall shape to those produced by the Abcam antibody ( Supplementary  Fig. 2 ). We detected 33,157 peaks in this library that mapped to mRNAs. These peaks had a high degree of positional overlap (89.06%) with the Abcam peaks (Fig. 2a) .
We next sought to validate that C→T transitions induced by the Abcam antibody could be found at m6A residues throughout the transcriptome. Biochemical experiments have demonstrated that most m6A in mRNA is located in a GAC or AAC sequence 16 , and indeed, we found that GAC and AAC were strongly enriched at transition sites (Fig. 2b) . Furthermore, the GGA and ACT triplets were enriched at −1 and +1 positions, respectively, recapitulating the most prevalent m6A consensus sequence, GGACT (Fig. 2b) . Thus, we concluded that C→T transitions predominantly occur at m6A consensus motifs.
To call C→T transitions, we used a computational pipeline designed for the identification of cross-linking-induced mutation sites (CIMSs) in high-throughput sequencing CLIP data 17 (Online Methods). This resulted in a set of 11,832 called sites. This set was enriched in adenosines at the −1 position of C→T transitions (80.59%), supporting the notion that these transitions largely reflect m6A. Furthermore, 77.29% of these adenosines occurred in a DRACH consensus motif, a value that is significantly higher than would be expected on the basis of the background distribution of this motif in mRNA ( Fig. 2c ; P < 1 × 10 −15 , Fisher's exact test). CIMS-based miCLIP (CIMS miCLIP) identified 9,536 putative m6A residues in the transcriptome (Supplementary Table 1 and Supplementary Fig. 3b ).
identification of m6A using antibody-induced truncations
To analyze truncations in the SySy library, we used a computational pipeline for detecting cross-linking-induced truncation sites (CITSs) in CLIP data 18 . This resulted in 8,329 significant (P < 0.05) truncation sites that mapped to mRNAs. Most of these truncations occurred at adenosines (77.10%). CITS-based miCLIP (CITS miCLIP) identified 6,543 putative m6A sites (Supplementary Table 2 ). These were significantly enriched in DRACH consensus sites ( Fig. 2c ; 79.46%, P < 1 × 10 −15 , Fisher's exact test).
Validation of m6A residues identified by micliP
Both CIMS-and CITS-called sites were localized predominantly in the coding sequence and the 3′ UTR of mRNA ( Supplementary  Fig. 3a) , consistent with the known distribution of m6A 1, 2 . Sequence logo analysis of both data sets confirmed that called sites occurred in the m6A consensus motif DRACH (Fig. 2d) . Additionally, both metagene profiles followed the typical distribution of m6A with strong enrichment at the stop codon (Fig. 2e) . These data suggest that miCLIP identifies true m6A residues.
Next, we examined the accuracy of m6A identification by miCLIP. We compared miCLIP sites to a control set of adenosines that had been biochemically validated for their N 6 -methylation status using the thin-layer chromatographybased method SCARLET 19 . This data set included a positive control set of eight m6A residues in five transcripts, as well as 15 adenosine residues in a DRACH sequence context that were not methylated.
To estimate the sensitivity and specificity of miCLIP, we determined the number of SCARLET-positive and SCARLET-negative sites that were called (Supplementary Fig. 3c ). CIMS and CITS miCLIP identified six and five of the eight SCARLET-positive sites, respectively. Importantly, none of the 15 SCARLET-negative sites were called by CIMS miCLIP, and only one was called by CITS miCLIP. Despite the small size of the SCARLET-derived set, this suggests that miCLIP detects m6A with high specificity and sensitivity. (e) miCLIP-identified m6A residues showed a metagene distribution profile typical for m6A. Metagene distribution plots of DRACH consensus site background (black) and the m6A residues predicted by CIMS-based (yellow) and CITS-based (gray) miCLIP.
npg
The accuracy of miCLIP could be seen when we examined individual transcripts. For example, in MALAT1, three SCARLETnegative sites were located in a 110-nt window between two SCARLET-positive m6A residues (Fig. 3) . Although both SCARLETpositive sites were correctly identified by CIMS and CITS miCLIP, none of the interspersed negative sites were called. Thus, miCLIP showed excellent spatial resolution and a low false discovery rate. m6A in clusters and infrequently methylated drAch motifs Clustered m6A residues have been predicted from the shape, size and distribution of MeRIP-Seq peaks 1 . Using CIMS miCLIP, we identified 958 clusters ranging in size from ~150 to ~500 nt (Online Methods and Supplementary Fig. 4a ) that contained up to 15 m6A residues (Supplementary Fig. 4b ). The average distance between m6As in these clusters was 64 nt.
Because MeRIP-Seq peaks are typically ~100-200 nt wide and the bioinformatic prediction of m6A residues is limited to one site per peak 5 , this approach misses a substantial portion of clustered m6As. Indeed, although m6A clusters had 2.39 miCLIPcalled m6As on average, they contained only 1.06 MeRIPSeq-predicted m6As. This indicates that peak-based prediction algorithms may miss more than half of m6A residues occurring in clusters. In contrast, miCLIP identified individual m6A residues separated by as few as 3 nt (Supplementary Fig. 4c) .
Bioinformatics methods use a predefined subset of consensus motifs to predict the m6A residue within a peak, according to the idea that some DRACH pentamers are preferred targets for methylation 5 . However, this approach misses m6As that occur in motifs outside of this predefined subset. As miCLIP does not require a priori assumptions about the sequence context of m6A (except for the invariant cytosine in CIMS miCLIP), it identifies m6A in all possible motifs. We determined the exact distribution of consensus sequences in which m6A occurs ( Supplementary  Fig. 5 ). Our findings confirmed that most m6A residues reside in a subset of DRACH motifs 5 . In fact, 41% and 50% of m6A residues detected by CIMS and CITS miCLIP, respectively, resided in just four subtypes of the DRACH motif. However, a considerable portion of m6As (23% and 31% as determined by CITS and CIMS miCLIP, respectively) occurred in DRACH motifs that would be missed by bioinformatic prediction. cits micliP identifies m6Am at the tss We next asked whether miCLIP can identify m6Am, a related base modification found in certain mRNAs in the first position after the 7-methylguanosine cap 12 . The function of m6Am is poorly understood; thus, mapping m6Am is important for elucidating its functional role in vivo.
Unlike m6A, which is not detected at the first position of mRNA, m6Am is limited to the first position in transcripts 12 .
Recently, a MeRIP-Seq approach coupled with bioinformatic analysis that detects RNA 5′ ends was used to predict methylated adenines at transcription start sites (TSSs) 5 . We reasoned that miCLIP could also be used to map m6Am at TSSs throughout the transcriptome. Indeed, the metagene profile of sites identified by CITS miCLIP showed an enrichment of called sites in the 5′ UTR (Fig. 2e) . This enrichment was absent in CIMS miCLIP (Fig. 2e) , presumably because CIMS miCLIP requires a C at the +1 position of the modified A.
Because CITS miCLIP is not dependent on sequence context, we reasoned that it could identify m6Am at the TSS. We analyzed 797 truncations localized to 5′ UTRs and found that they occurred in the canonical m6A motif DRACH, as well as in a BCA* motif (where B denotes C, U or G, and A* denotes methylatable A) (Fig. 4a) . 5′ UTRs contained nearly three times as many methylated BCA motifs as DRACH motifs (434 sites versus 151 sites). Interestingly, the extended form of the BCA motif (Fig. 4a) resembled the known pyrimidine-rich sequence at TSSs [20] [21] [22] [23] , further suggesting that these sites were m6Am rather than internal m6A.
To further address the position of putative m6Am sites, we performed metagene analysis of truncations occurring in DRACH and BCA sequence contexts (Fig. 4b) . Whereas truncations in DRACH sites followed the canonical m6A distribution, truncations in BCA sequence contexts localized primarily to the 5′ UTR (Fig. 4b) , with the greatest enrichment near the annotated TSS (Fig. 4c) .
Finally, we sought to validate the idea that CITS miCLIP recognizes m6Am by comparing our data to a known set of m6Am-containing mRNAs 24 . We focused on histone mRNAs, which have been biochemically shown to start with m6Am 24 . Indeed, CITS miCLIP called truncation sites at the m6Am position of three histone mRNAs (Fig. 4d) . Importantly, the truncation efficiency at these sites was not 100%, which indicated that these truncations were induced by antibody cross-linking rather than reverse transcriptase reaching the transcript end ( Fig. 4d and  Supplementary Fig. 6 ). These data show that CITS miCLIP was able to detect two distinct RNA modifications, m6A and m6Am, at single-nucleotide resolution throughout the transcriptome.
cims micliP identifies m6A residues in snornAs An important criterion for calling peaks in MeRIP-Seq is that peaks must be higher than piled-up reads in adjacent areas in the same transcript, which define the background read level 1 . However, small RNAs can be entirely covered with reads, making However, because CIMS miCLIP identifies C→T transitions, m6A residues can be readily detected in small RNAs by that method.
To validate that CIMS miCLIP can detect m6A residues in small RNAs, we focused on snoRNAs. C→T transitions identified m6A residues in both H/ACA and C/D box snoRNA subclasses, with more than 25% of both classes having at least one m6A (Fig. 5a,b) . For example, we detected a high rate of C→T transitions in snoRNAs Snora64 and Snord2 (Fig. 5c) . These transitions were found in typical DRACH motifs (Fig. 5d) . The discovery of m6A in snoRNAs complements the finding of pseudouridine in snoRNAs 25 , which suggests that this class of ncRNAs is regulated by diverse RNA modifications. discussion m6A is the most widespread base modification in mRNA, but a method for identifying specific residues has been lacking. We showed that m6A residues can be mapped by generating signature mutations with m6A-specific antibodies and UV cross-linking. We mapped m6A residues using two antibodies, each of which had specific advantages: one antibody produced a C→T transition that was limited to detecting m6A but could readily detect clustered m6A residues, and the other antibody produced truncations that could be used to map m6A and m6Am residues simultaneously. Although our experiments used specific antibodies, our approach to screening cross-link-induced mutations should make it straightforward to identify other m6A antibodies suitable for miCLIP. This approach could additionally be used to map other RNA modifications for which antibodies exist. npg An important feature of miCLIP is that it can be used without pretreatment of cells with modified nucleotides such as 4-thiouracil (4SU), which is used in photoactivatable ribonucleoside-enhanced (PAR)-CLIP 10 . Indeed, in a recent study antibodies to m6A were cross-linked to 4SU-labeled RNA 26 . RNA fragments that cross-linked to the antibody contained characteristic T→C mutations arising from 4SU cross-links. This strategy is valuable, as it reduces noise by identifying and narrowing PAR-CLIP peak clusters. However, in that study the T→C mutations were not used to map specific m6A residues throughout the transcriptome. Unlike miCLIP, which is associated with signature mutations, PAR-CLIP experiments can generate multiple 4SU transitions at protein-binding sites in transcripts 10 . Because of the inconsistent number and position of transitions relative to each m6A residue, it is challenging to use T→C mutations for m6A identification. In contrast, miCLIP relies on characteristic mutational signatures that are highly predictive of m6A residues.
Direct identification of m6A provides advantages over bioinformatic prediction of m6A residues from MeRIP-Seq peaks. Bioinformatic prediction is reliable if the m6A peak has a single clear summit, is caused by a single m6A residue and has a single centrally located DRACH motif. However, m6A residues are often clustered in mRNAs 1 . As a result, MeRIP-Seq peaks are often broad with diverse shapes, and the summits of these peaks might not reflect the position of the m6A residues that account for the peak shape. In miCLIP, peak shape does not influence m6A identification. Furthermore, miCLIP does not constrain m6A identification to m6A residues that fall within a specified subset of DRACH motifs. Thus, miCLIP enables unbiased identification of m6A residues.
The inability to identify specific methylated adenosines in mRNA at single-nucleotide resolution has hampered functional studies of m6A. Indeed, recent studies proposing functions for m6A have not mutated specific adenosine residues to unequivocally determine the effect of m6A on a specific transcript. The single-nucleotide data set presented here will make it straightforward to test the role of any m6A in determining the fate or function of any transcript. In vitro mutagenesis assay. A 1,502-nt-long RNA containing a single adenosine nucleotide at position 966 was transcribed in the presence of GTP, CTP, UTP and either ATP or m 6 ATP with the Ampliscribe in vitro transcription kit (Epicentre). Then 6 µg of the fragmented transcript were incubated with 4 µg of each of the m6A antibodies tested. After UV cross-linking with 0.15 J cm −2 UV light (254 nm), antibody-RNA complexes were processed as described for cellular RNA, and a library was prepared for each antibody. Libraries were then sequenced on a MiSEQ instrument, and reads covering the m6A position with single mismatches at positions −2 to +4 were quantified. For each nucleotide at positions −2 to +4 of the m6A, we determined the frequency of truncation and transition events. For this, reads terminating at a given position (for truncations) and single-nucleotide mismatches at that position (for transitions) were counted and normalized to the total number of reads covering the m6A residue.
Cell lines and animals. For characterizing m6A residues in humans, we used HEK293 cells (CRL-1573, ATCC). Cells were tested for mycoplasma by Hoechst staining. Cell-line verification was not performed. For profiling m6A residues in mice, we used mouse liver (Charles River; CD-1/ICR, female, 8-10 weeks old). All experiments involving mice were approved by the Institutional Animal Care and Use Committee at Weill Cornell Medical College.
Preparation of mouse liver nuclei. For the identification of m6A residues in small nucleolar RNAs (snoRNAs), we collected intact nuclei from mouse liver using an iodixanol gradient as described previously 27 . All steps were performed at 4 °C. In brief, liver was homogenized in hypo-osmotic medium (250 mM sucrose, 25 mM KCl, 5 mM MgCl 2 , 10 mM Tris-HCl, pH 7.4) with a dounce homogenizer. The homogenate was then mixed with 50% iodixanol (D1556, Sigma-Aldrich, diluted with 250 mM sucrose, 150 mM KCl, 30 mM MgCl 2 , 60 mM Tris-HCl, pH 7.4) to a final concentration of 25% iodixanol. This mixture was then underlayered with 30% and 35% iodixanol and centrifuged in a swinging-bucket rotor for 20 min at 10,000g. Nuclear bands were collected, and nuclear RNA was extracted with Trizol (Life Technologies).
Cross-linking of cellular RNA. For initial miCLIP libraries, total RNA was purified from HEK293 cells. Poly(A) + RNA was prepared from four biological replicates of HEK293 cells and processed in parallel for miCLIP. Mouse liver RNA was depleted of ribosomal RNA by Ribominus (Life Technologies).
We used fragmentation reagent (Life Technologies) to fragment RNA to a size between 30 and 130 nt. After the reaction had been stopped, 20 µg fragmented RNA was directly diluted in 450 µl immunoprecipitation buffer (50 mM Tris, pH 7.4, 100 mM NaCl, 0.05% NP-40) and incubated with 1-5 µg anti-m6A at 4 °C for 1-2 h, rotating head over tail. The solution was then transferred into a 3-cm cell culture dish and cross-linked twice with 0.15 J cm −2 UV light (254 nm) in a Stratalinker (Agilent).
After cross-linking, the solution was transferred into Eppendorf tubes and incubated with 30 µl Protein A/G beads (Thermo Scientific) for 1-2 h at 4 °C, rotating. Bead-bound antibody-RNA complexes were then recovered on a magnetic stand (Life Technologies) and washed twice with high-salt buffer (50 mM Tris, pH 7.4, 1 M NaCl, 1 mM EDTA, 1% NP-40, 0.1% SDS), twice with immunoprecipitation buffer, and twice with polynucleotide kinase (PNK) wash buffer (20 mM Tris, 10 mM MgCl 2 , 0.2% Tween 20).
3′ dephosphorylation, linker ligation and labeling. The protocol for these steps was similar to the protocol described for iCLIP 9 . In brief, RNA 3′ ends were dephosphorylated on beads with PNK (M0201S, New England BioLabs) for 30 min in dephosphorylation buffer (70 mM Tris, pH 6.5, 10 mM MgCl 2 , 1 mM DTT). After another round of extensive washing (twice with PNK wash buffer, once with immunoprecipitation buffer, once with highsalt buffer, and twice with PNK wash buffer), the 3′ adaptor was ligated with T4 RNA ligase (New England BioLabs) overnight. Antibody-RNA complexes were then eluted from beads with 1× NuPage sample buffer (Life Technologies) containing 50 mM DTT, subjected to NuPage gel electrophoresis and transferred onto 0.45-µm nitrocellulose membranes (Bio-Rad). After autoradiography (2 h to overnight), membrane regions containing RNA-cross-linked antibody heavy and light chains were excised and the RNA was released from the membrane by treatment with proteinase K (Life Technologies).
Library preparation. After phenol-chloroform extraction and precipitation, the RNA was reverse transcribed with Superscript III reverse transcriptase (Life Technologies) according to the manufacturer's protocol. First-strand cDNA was size-selected on a 6% TBE-Urea gel (Life Technologies), and regions corresponding to 80-120 nt (for the total RNA data set) or 70-100 nt (for the mRNA data set) were used for further analysis. Circularization and re-linearization of cDNA were performed as described in the iCLIP protocol 9 . Libraries were PCR amplified for 18-21 cycles and sequenced on an Illumina HiSeq 2500 instrument.
Read preprocessing. Fastq files were adaptor trimmed using flexbar 28 and demultiplexed on the basis of their experimental barcode using the pyBarcodeFilter.py script of the pyCRAC tool suite 29 . The second part of the iCLIP random barcode was then moved to the read headers with the Unix tool awk (awk -F "##" '{sub(/..../,"##"$2, $2); getline($3); $4 = substr($3,1,2); $5 = substr($3,3); print $1 $2 $4"\n"$5}'). For the HEK293 mRNA data set (CIMS miCLIP), reads from the four replicates were combined at this point. Sequence-based removal of PCR duplicates was then performed with the pyFastqDuplicateRemover.py script 29 . Awk was then used to generate read headers compatible with downstream processing by the CIMS pipeline (awk -F '[_/]' '/^>/{print $1"_"$2"_"$3"/"$4"#"$3"#"$2; getline($9); print $9}').
Processing of paired-end data. To increase base coverage and thus facilitate the discrimination of mutations (which should be at the same position in both reads) from random sequencing errors (which should be evenly distributed in the reads), we generated short insert libraries (~30-40 nt) and subjected them to paired-end sequencing. For these paired-end data, reverse npg
